Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) will host a virtual investor call on October 11 to update on its latest Phase I/II BEXMAB data for treating acute myeloid leukaemia and myelodysplastic syndrome. It will take place at 08.00 EST/13.00 BST/15.00 EEST. To register click here.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com